Department of Biosciences, Jamia Millia Islamia, New Delhi, India.
Translational Bioinformatics Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
IUBMB Life. 2021 Jul;73(7):941-952. doi: 10.1002/iub.2475. Epub 2021 May 1.
Neuroserpin is a serine protease inhibitor expressed mainly in the brain and at low levels in other tissues like the kidney, testis, heart, and spinal cord. It is involved in the inhibition of tissue plasminogen activator (tPA), plasmin, and to a lesser extent, urokinase-type plasminogen (uPA). Neuroserpin has also been shown to plays noninhibitory roles in the regulation of N-cadherin-mediated cell adhesion. It is involved in neuroprotection from seizure and stroke through tPA-mediated inhibition and also through its other protease targets. Mutations in critical domains of neuroserpin lead to its polymerization and neuronal death. In this study, a novel truncated isoform of human neuroserpin was identified in the brain and liver, which was confirmed by reverse transcriptase-PCR and DNA sequencing using exon-specific primers. Structural characterization of novel isoform using MD simulations studies indicated that it lacks the reactive center loop (RCL) but largely maintains its secondary structure fold. The novel truncated variant was cloned, expressed, and purified. A comparative intrinsic fluorescence and 4,4'-bis-1-anilino naphthalene 8-sulfonate studies revealed a decrease in fluorescence emission intensity and a more exposed hydrophobic surface as compared to the reported isoform. However, the novel isoform has lost its ability for tPA inhibition and complex formation. The absence of RCL indicates a noninhibitory role for the truncated isoform, prompting a detailed search and identification of two smaller isoforms in the human brain. With indications of the noninhibitory role of neuroserpin, identifying novel isoforms that appear to be without the tPA recognition domain is significant.
神经丝氨酸蛋白酶抑制剂是一种主要在大脑中表达、在肾脏、睾丸、心脏和脊髓等其他组织中低水平表达的丝氨酸蛋白酶抑制剂。它参与组织型纤溶酶原激活物(tPA)、纤溶酶和在较小程度上尿激酶型纤溶酶原(uPA)的抑制。神经丝氨酸蛋白酶抑制剂还被证明在调节 N-钙粘蛋白介导的细胞黏附中发挥非抑制作用。它通过 tPA 介导的抑制以及通过其其他蛋白酶靶标参与保护免受癫痫发作和中风的影响。神经丝氨酸蛋白酶抑制剂关键结构域的突变导致其聚合和神经元死亡。在这项研究中,在大脑和肝脏中鉴定到一种新型截短的人神经丝氨酸蛋白酶抑制剂同工型,通过使用exon 特异性引物的逆转录 PCR 和 DNA 测序得到证实。使用 MD 模拟研究对新型同工型的结构特征进行了表征,结果表明它缺乏反应中心环(RCL),但在很大程度上保持了其二级结构折叠。新型截短变体被克隆、表达和纯化。比较荧光强度和 4,4'-双-1-苯胺基萘 8-磺酸盐研究表明,与报道的同工型相比,荧光发射强度降低,疏水性表面暴露更多。然而,新型同工型已失去其对 tPA 抑制和复合物形成的能力。缺乏 RCL 表明截短同工型具有非抑制作用,促使在人脑中详细搜索和鉴定两种更小的同工型。由于神经丝氨酸蛋白酶抑制剂具有非抑制作用,因此鉴定似乎没有 tPA 识别结构域的新型同工型具有重要意义。